Early QT/TQT Studies

If you're planning cardiac safety studies, the choice of site matters more than most sponsors realize. Dr. Vince Clinical Research (DVCR) operates a Clario-certified Phase I unit built specifically for Early Precision QT (EPQT) and Thorough QT (TQT) analysis, the studies that determine how a drug affects the cardiac conduction cycle and whether it poses arrhythmia risk.

The site runs 48 individual monitoring channels on the Hillrom Surveyor cardiac telemetry system, with data transmitting directly to Clario's cloud-based portal and remote tracing quality oversight to minimize interruptions. Fewer electrodes on participants is a small detail that actually matters for volunteer retention and comfort over long collection windows.

What makes the Clario certification worth noting: DVCR's EPQT capability is designed to satisfy ICH E14 regulatory requirements, which opens the door to waiving a full TQT study entirely. That's a meaningful timeline and cost consideration for early-phase sponsors. Robert Kleiman, M.D., Chief Science and Regulatory Advisor at Clario, called the unit "exceptionally well-suited" for these complex trials.

Contact DVCR at DrVinceCRO.com to discuss whether an EPQT approach could replace your TQT requirement.